Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Medical Officer | February 02, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date February 02, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,000 |
Reported balance
After 2026-02-02 transaction · row 1
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 44,000 · Balance 44,000 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on February 1, 2027. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2036-02-01 | Direct | 154,000 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 154,000 · Balance 154,000 F2: 25% of the shares subject to the option vest on February 26, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on February 1, 2027.
F2: 25% of the shares subject to the option vest on February 26, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 5, 2026 01:01 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 154,000 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0002108554-26-000004 · form4-02052026_010237.xml · derivative · entry 2 Go William · CIK 0002108554 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,000 Underlying: Common Stock · 154,000 shares Expires 2036-02-01 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on February 26, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:01 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002108554-26-000004 · form4-02052026_010237.xml · nonDerivative · entry 1 Go William · CIK 0002108554 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on February 1, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.